Development of intranasal implantable devices for schizophrenia treatment

In this work the preparation and characterisation of intranasal implants for the delivery of risperidone (RIS) is described. The aim of this work is to develop better therapies to treat chronic conditions affecting the brain such as schizophrenia. This type of systems combines the advantages of intr...

ver descrição completa

Detalhes bibliográficos
Autores: Utomo, E. (Emilia)|||/items/b2ddcb38-be5a-493e-9853-0f18838da099, Domínguez-Robles, J. (Juan)|||/items/b2398c6e-1d4b-4195-8324-576a14336499, Moreno-Castellanos, N. (Natalia)|||/items/acf3ca16-ae2d-4674-8925-14d3142d5d2b, Stewart, S.A. (Sarah A.)|||/items/344402c1-35bb-46bd-8c07-f7be58b03b94, Picco, C.J. (Camila J.)|||/items/5f003d84-2450-40a9-a3d6-edc841cf81a6, Kurnia-Anjani, Q. (Qonita)|||/items/46a0e9f3-c961-4840-8df5-d46ce189d1c9, Simón-Martínez, J.A. (Jon Ander)|||/items/4999ee65-f95e-46f0-9f17-4c90647b6504, Peñuelas-Sanchez, I. (Ivan)|||/items/7022e2fa-b3b0-48ed-8d39-2020cfae85a4, Donnelly, R. (Ryan)|||/items/2e24ddec-11a4-4147-bf16-94614bd2385e, Larrañeta, E. (Eneko)|||/items/dfeb2f8f-aa42-45ef-82fe-d61110bb0166
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dnet:dadun_______::e78dc5fd094d95820cb7eccd13137103
Acesso em linha:https://hdl.handle.net/10171/124037
Access Level:acceso abierto
Palavra-chave:Implantable devices
Intranasal drug delivery
Poly(caprolactone)
Poly(lactic-co- glycolic acid) acid
Prolonged drug release
Risperidone
id ES_de20a28e79a9596e75dd5f5aeaa712a1
oai_identifier_str oai:dnet:dadun_______::e78dc5fd094d95820cb7eccd13137103
network_acronym_str ES
network_name_str España
repository_id_str
spelling Development of intranasal implantable devices for schizophrenia treatmentUtomo, E. (Emilia)|||/items/b2ddcb38-be5a-493e-9853-0f18838da099Domínguez-Robles, J. (Juan)|||/items/b2398c6e-1d4b-4195-8324-576a14336499Moreno-Castellanos, N. (Natalia)|||/items/acf3ca16-ae2d-4674-8925-14d3142d5d2bStewart, S.A. (Sarah A.)|||/items/344402c1-35bb-46bd-8c07-f7be58b03b94Picco, C.J. (Camila J.)|||/items/5f003d84-2450-40a9-a3d6-edc841cf81a6Kurnia-Anjani, Q. (Qonita)|||/items/46a0e9f3-c961-4840-8df5-d46ce189d1c9Simón-Martínez, J.A. (Jon Ander)|||/items/4999ee65-f95e-46f0-9f17-4c90647b6504Peñuelas-Sanchez, I. (Ivan)|||/items/7022e2fa-b3b0-48ed-8d39-2020cfae85a4Donnelly, R. (Ryan)|||/items/2e24ddec-11a4-4147-bf16-94614bd2385eLarrañeta, E. (Eneko)|||/items/dfeb2f8f-aa42-45ef-82fe-d61110bb0166Implantable devicesIntranasal drug deliveryPoly(caprolactone)Poly(lactic-co- glycolic acid) acidProlonged drug releaseRisperidoneIn this work the preparation and characterisation of intranasal implants for the delivery of risperidone (RIS) is described. The aim of this work is to develop better therapies to treat chronic conditions affecting the brain such as schizophrenia. This type of systems combines the advantages of intranasal drug delivery with sustained drug release. The resulting implants were prepared using biodegradable materials, including poly(caprolactone) (PCL) and poly(lactic-co-glycolic acid) (PLGA). These polymers were combined with water-soluble compounds, such as poly(ethylene glycol) (PEG) 600, PEG 3000, and Tween® 80 using a solvent-casting method. The resulting implants contained RIS loadings ranging between 25 and 50 %. The obtained implants were characterised using a range of techniques including thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), attenuated total reflectance-Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), and Scanning Electron Microscopy (SEM). Moreover, in vitro RIS release was evaluated showing that the addition of water-soluble compounds exhibited significant faster release profiles compared to pristine PCL and PLGA-based implants. Interestingly, PCL-based implants containing 25 % of RIS and PLGA-based implants loaded with 50 % of RIS showed sustained drug release profiles up to 90 days. The former showed faster release rates over the first 28 days but after this period PLGA implants presented higher release rates. The permeability of RIS released from the implants through a model membrane simulating nasal mucosa was subsequently evaluated showing desirable permeation rate of around 2 mg/day. Finally, following in vitro biocompatibility studies, PCL and PLGA-based implants showed acceptable biocompatibility. These results suggested that the resulting implants displayed potential of providing prolonged drug release for brain-targeting drugs.ElsevierDadun. Depósito Académico Digital Universidad de Navarra20222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/124037reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dnet:dadun_______::e78dc5fd094d95820cb7eccd131371032026-06-21T12:47:57Z
dc.title.none.fl_str_mv Development of intranasal implantable devices for schizophrenia treatment
title Development of intranasal implantable devices for schizophrenia treatment
spellingShingle Development of intranasal implantable devices for schizophrenia treatment
Utomo, E. (Emilia)|||/items/b2ddcb38-be5a-493e-9853-0f18838da099
Implantable devices
Intranasal drug delivery
Poly(caprolactone)
Poly(lactic-co- glycolic acid) acid
Prolonged drug release
Risperidone
title_short Development of intranasal implantable devices for schizophrenia treatment
title_full Development of intranasal implantable devices for schizophrenia treatment
title_fullStr Development of intranasal implantable devices for schizophrenia treatment
title_full_unstemmed Development of intranasal implantable devices for schizophrenia treatment
title_sort Development of intranasal implantable devices for schizophrenia treatment
dc.creator.none.fl_str_mv Utomo, E. (Emilia)|||/items/b2ddcb38-be5a-493e-9853-0f18838da099
Domínguez-Robles, J. (Juan)|||/items/b2398c6e-1d4b-4195-8324-576a14336499
Moreno-Castellanos, N. (Natalia)|||/items/acf3ca16-ae2d-4674-8925-14d3142d5d2b
Stewart, S.A. (Sarah A.)|||/items/344402c1-35bb-46bd-8c07-f7be58b03b94
Picco, C.J. (Camila J.)|||/items/5f003d84-2450-40a9-a3d6-edc841cf81a6
Kurnia-Anjani, Q. (Qonita)|||/items/46a0e9f3-c961-4840-8df5-d46ce189d1c9
Simón-Martínez, J.A. (Jon Ander)|||/items/4999ee65-f95e-46f0-9f17-4c90647b6504
Peñuelas-Sanchez, I. (Ivan)|||/items/7022e2fa-b3b0-48ed-8d39-2020cfae85a4
Donnelly, R. (Ryan)|||/items/2e24ddec-11a4-4147-bf16-94614bd2385e
Larrañeta, E. (Eneko)|||/items/dfeb2f8f-aa42-45ef-82fe-d61110bb0166
author Utomo, E. (Emilia)|||/items/b2ddcb38-be5a-493e-9853-0f18838da099
author_facet Utomo, E. (Emilia)|||/items/b2ddcb38-be5a-493e-9853-0f18838da099
Domínguez-Robles, J. (Juan)|||/items/b2398c6e-1d4b-4195-8324-576a14336499
Moreno-Castellanos, N. (Natalia)|||/items/acf3ca16-ae2d-4674-8925-14d3142d5d2b
Stewart, S.A. (Sarah A.)|||/items/344402c1-35bb-46bd-8c07-f7be58b03b94
Picco, C.J. (Camila J.)|||/items/5f003d84-2450-40a9-a3d6-edc841cf81a6
Kurnia-Anjani, Q. (Qonita)|||/items/46a0e9f3-c961-4840-8df5-d46ce189d1c9
Simón-Martínez, J.A. (Jon Ander)|||/items/4999ee65-f95e-46f0-9f17-4c90647b6504
Peñuelas-Sanchez, I. (Ivan)|||/items/7022e2fa-b3b0-48ed-8d39-2020cfae85a4
Donnelly, R. (Ryan)|||/items/2e24ddec-11a4-4147-bf16-94614bd2385e
Larrañeta, E. (Eneko)|||/items/dfeb2f8f-aa42-45ef-82fe-d61110bb0166
author_role author
author2 Domínguez-Robles, J. (Juan)|||/items/b2398c6e-1d4b-4195-8324-576a14336499
Moreno-Castellanos, N. (Natalia)|||/items/acf3ca16-ae2d-4674-8925-14d3142d5d2b
Stewart, S.A. (Sarah A.)|||/items/344402c1-35bb-46bd-8c07-f7be58b03b94
Picco, C.J. (Camila J.)|||/items/5f003d84-2450-40a9-a3d6-edc841cf81a6
Kurnia-Anjani, Q. (Qonita)|||/items/46a0e9f3-c961-4840-8df5-d46ce189d1c9
Simón-Martínez, J.A. (Jon Ander)|||/items/4999ee65-f95e-46f0-9f17-4c90647b6504
Peñuelas-Sanchez, I. (Ivan)|||/items/7022e2fa-b3b0-48ed-8d39-2020cfae85a4
Donnelly, R. (Ryan)|||/items/2e24ddec-11a4-4147-bf16-94614bd2385e
Larrañeta, E. (Eneko)|||/items/dfeb2f8f-aa42-45ef-82fe-d61110bb0166
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv Implantable devices
Intranasal drug delivery
Poly(caprolactone)
Poly(lactic-co- glycolic acid) acid
Prolonged drug release
Risperidone
topic Implantable devices
Intranasal drug delivery
Poly(caprolactone)
Poly(lactic-co- glycolic acid) acid
Prolonged drug release
Risperidone
description In this work the preparation and characterisation of intranasal implants for the delivery of risperidone (RIS) is described. The aim of this work is to develop better therapies to treat chronic conditions affecting the brain such as schizophrenia. This type of systems combines the advantages of intranasal drug delivery with sustained drug release. The resulting implants were prepared using biodegradable materials, including poly(caprolactone) (PCL) and poly(lactic-co-glycolic acid) (PLGA). These polymers were combined with water-soluble compounds, such as poly(ethylene glycol) (PEG) 600, PEG 3000, and Tween® 80 using a solvent-casting method. The resulting implants contained RIS loadings ranging between 25 and 50 %. The obtained implants were characterised using a range of techniques including thermogravimetric analysis (TGA), differential scanning calorimetry (DSC), attenuated total reflectance-Fourier transform infrared (ATR-FTIR), X-ray diffraction (XRD), and Scanning Electron Microscopy (SEM). Moreover, in vitro RIS release was evaluated showing that the addition of water-soluble compounds exhibited significant faster release profiles compared to pristine PCL and PLGA-based implants. Interestingly, PCL-based implants containing 25 % of RIS and PLGA-based implants loaded with 50 % of RIS showed sustained drug release profiles up to 90 days. The former showed faster release rates over the first 28 days but after this period PLGA implants presented higher release rates. The permeability of RIS released from the implants through a model membrane simulating nasal mucosa was subsequently evaluated showing desirable permeation rate of around 2 mg/day. Finally, following in vitro biocompatibility studies, PCL and PLGA-based implants showed acceptable biocompatibility. These results suggested that the resulting implants displayed potential of providing prolonged drug release for brain-targeting drugs.
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01
2022
2022-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/124037
url https://hdl.handle.net/10171/124037
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421945963937792
score 15,812429

Registos relacionados